文献速递角膜与眼表疾病

间充质干细胞来源外泌体miR-223-3p通过下调Fbxw7减轻干眼模型眼表损伤与炎症

Mesenchymal Stem Cells-Derived Exosomal miR-223-3p Alleviates Ocular Surface Damage and Inflammation by Downregulating Fbxw7 in Dry Eye Models.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

本研究在小鼠干眼模型中探究脂肪间充质干细胞外泌体来源miR-223-3p的疗效与机制。结果显示miR-223-3p可改善苯扎氯铵或东莨菪碱诱导的干眼小鼠眼表损伤并降低促炎因子,其作用与靶向抑制Fbxw7相关,提示其可能成为干眼治疗选择。

要点

  • 敲除miR-223-3p的mADSC-Exos不能降低IL-6含量,补充miR-223-3p可恢复该降低作用。
  • miR-223-3p在BAC和Scop诱导的小鼠干眼模型中均改善眼表损伤并降低促炎因子或趋化因子。
  • Fbxw7是miR-223-3p的潜在直接靶点,敲低Fbxw7可抑制高渗诱导的MCECs炎症。

核心结论

  • mADSC来源外泌体miR-223-3p减轻眼表损伤和炎症,提示其可能成为干眼的有前景治疗选择。

研究设计与样本

  • 研究采用高渗诱导的小鼠角膜上皮细胞(MCECs)进行体外实验,并在BAC或Scop诱导的小鼠干眼模型中评估miR-223-3p疗效。
  • 小鼠随机分为5组:假手术组、模型组、miR-223-3p过表达组、miR-223-3p敲低组和0.1%普拉洛芬阳性组。

主要发现

  • 敲除miR-223-3p的mADSC-Exos不降低IL-6含量,补充miR-223-3p可恢复IL-6的降低。
  • miR-223-3p在BAC和Scop诱导的小鼠干眼模型中均有效改善眼表损伤并降低促炎细胞因子或趋化因子。
  • miR-223-3p抑制细胞凋亡,Fbxw7是miR-223-3p的潜在直接靶点,miR-223-3p抑制Fbxw7的3‘非翻译区。
  • 敲低Fbxw7抑制高渗诱导的MCECs炎症。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our previous study indicated that exosomes derived from mouse adipose-derived mesenchymal stem cells (mADSC-Exos) alleviated the benzalkonium chloride (BAC)-induced mouse dry eye model. However, the specific active molecules in mADSC-Exos that contribute to anti-dry eye therapy remain unidentified. In this study, we aimed to investigate the efficacy and mechanisms of miR-223-3p derived from mADSC-Exos in dry eye models. METHODS: Enzyme-linked immunosorbent assay (ELISA) experiments were conducted to determine miR-223-3p derived from mADSC-Exos that exerted anti-inflammatory effects on hyperosmolarity-induced mouse corneal epithelial cells (MCECs). The therapeutic efficacy of miR-223-3p was evaluated in mice with dry eye induced by either BAC or scopolamine (Scop). Mice were randomly assigned to 5 groups: sham, model, miR-223-3p overexpression, miR-223-3p knockdown, and 0.1% pranoprofen (positive group). Post-treatment, the severity of dry eye symptoms, and the pro-inflammatory cytokine levels were assessed. The effect of miR-223-3p on silencing the target gene was verified using ELISA and dual luciferase reporter assays. RESULTS: The mADSC-Exos that knocked out miR-223-3p did not reduce interleukin (IL)-6 content. Supplementing with miR-223-3p could restore the reduction of IL-6. The miR-223-3p effectively ameliorated ocular surface damage and decreased pro-inflammatory cytokines or chemokines in both BAC- and Scop-induced mouse dry eye models. Furthermore, miR-223-3p inhibited cell apoptosis. F-box and WD repeat domain-containing 7 (Fbxw7) was the potential direct target of miR-223-3p. The miR-223-3p suppressed the 3'-untranslated region of Fbxw7. The Fbxw7 knockdown suppressed hyperosmolarity-induced inflammation in MCECs. CONCLUSIONS: The mADSC-derived exosomal miR-223-3p mitigates ocular surface damage and inflammation, indicating its potential as a promising treatment option for dry eye.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Wang G, Zhu Y, Liu Y, et al. Mesenchymal Stem Cells-Derived Exosomal miR-223-3p Alleviates Ocular Surface Damage and Inflammation by Downregulating Fbxw7 in Dry Eye Models. Invest Ophthalmol Vis Sci. 2024. PMID: 39352716. doi:10.1167/iovs.65.12.1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。